Premium
Parathyroid hormone, but not prostaglandin E 2 , changes the shape of osteoblasts maintained on bone in vitro
Author(s) -
Boyde A.,
Jones Sheila J.,
Ali Nadire N.,
Melhuish Pauline B.,
Bennett A.
Publication year - 1990
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.5650050204
Subject(s) - osteoblast , periosteum , prostaglandin e2 , parathyroid hormone , endocrinology , medicine , chemistry , radioimmunoassay , in vitro , bone cell , prostaglandin e , bone remodeling , basal (medicine) , biology , anatomy , calcium , biochemistry , insulin
Parietal bones from 2‐week‐old rats were dissected free from the sutural regions, dura mater, and periosteum, leaving the surface covered with osteoblasts and some osteoclasts. Prostaglandin (PG) production by these “stripped” bones under basal conditions and after exposure to parathyroid hormone (PTH) was measured by radioimmunoassay of the culture medium (minimum essential medium with or without added 10% heat‐inactivated fetal calf serum). Cultured specimens were examined by scanning electron microscopy for changes in osteoblast length, orientation, ruffling, and overlap. As demonstrated previously, PTH caused the osteoblasts to elongate, align, and show fewer ruffles compared to controls. PTH increased PG synthesis by the stripped bones. Indomethacin inhibited PG formation but did not affect the osteoblast shape change. PGE 2 , indomethacin, or both drugs together had no discernible effect on any morphologic features. These findings indicate that PGE 2 does not change osteoblast shape and that the cell shape change with PTH is not mediated by endogenous prostanoids.